Skip to main content
Premium Trial:

Request an Annual Quote

University of California, Pandmics, Applied Gene Technologies, Kimberly-Clark Worldwide, 3M Innovative Properties


The Regents of the University of California received US Patent No. 6,696,271, “Frozen tissue microarray technology for analysis of RNA, DNA, and proteins.” The patent covers tissue microarray technology that utilizes uniform fixation across the array panel by using frozen tissues embedded in tissue-embedding compounds as donor samples and arraying the specimens into a recipient block comprising an embedding compound. Tissue is not fixed prior to embedding, and sections from the array are evaluated without fixation or post-fixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. Unlike paraffin tissue arrays, which can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, the disclosed methods allow optimal evaluation by each technique.

Pandmics of Redwood City, Calif., received US Patent No. 6,696,256, “Method, array and kit for detecting activated transcription factors by hybridization array.” The patent covers a system for rapidly and efficiently identifying and quantifying multiple different activated transcription factors in a biological sample simultaneously. The system includes the step of mixing a library of transcription factor probes with a sample containing activated transcription factors. The transcription factor probes that have bound to the activated transcription factors may be isolated from the complexes formed between the probes and the activated transcription factors. The bound probes can be identified, for example, by using an array of hybridization probes.

Applied Gene Technologies of San Diego received US Patent No. 6,696,255, “Nucleic acid hairpin probes and uses thereof.” This patent includes oligonucleotide probes containing hairpin structures, or arrays of such oligonucleotide probes immobilized on a solid support, which are suitable for hybridization analyses are described as well as a system for nucleic acid hybridization analysis using the probes or array of immobilized probes.

Kimberly-Clark Worldwide of Neenah, NJ, received US Patent No. 6,696,254, “Detection and identification of enteric bacteria.” The invention provides probes, antibodies and methods for detecting a gene that is only found in Enterobacteriaceae, the deoxyguanosine triphosphate triphosphohydrolase gene. These probes and methods are designed for detecting whether test samples, including food and water samples, are infected with enteric bacteria.

3M Innovative Properties of St. Paul, Minn., received US Patent No. 6,696,157, “Diamond-like glass thin films.” The patent includes a diamond-like glass film containing at least about 30 atomic percent carbon, at least about 25 atomic percent silicon, and less than or equal to about 45 atomic percent oxygen on a hydrogen-free basis. The diamond-like glass film may be applied to various substrates.


The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.